Pfizer seeds diabetes upstart AnTolRx with cash and an option deal
Pfizer is backing a newly minted biotech that is right at the very earliest stage of taking an academic program out of a Harvard lab and seeing if it can translate it into a successful development effort for Type 1 diabetes.
The new company is AnTolRx, based in Cambridge’s Kendall Square, which now has four full timers and a few key helpers as it builds a new program around a nanoparticle approach to simultaneously present an antigen and tolerance molecule to tamp down the autoimmune response that causes diabetes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.